Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brocard

Showing results (411-420 of 455) with videos related to

Pageof 46
Sort By:
Melanoma Research|November 11, 2024
Real-life effectiveness on overall survival of continued immune checkpoint inhibition following progression in advanced melanoma: estimation from the Melbase cohortCamille Macaire, Wendy Lefevre, Sophie Dalac, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 18, 2018
Sirolimus for Secondary Prevention of Skin Cancer in Kidney Transplant Recipients: 5-Year ResultsJacques Dantal, Emmanuel Morelon, Lionel Rostaing, et al.
Archives of Dermatology|March 17, 2010
The role of circumstances of diagnosis and access to dermatological care in early diagnosis of cutaneous melanoma: a population-based study in FranceFrédérique Durbec, Fabien Vitry, Florence Granel-Brocard, et al.
The New England Journal of Medicine|July 27, 2012
Sirolimus and secondary skin-cancer prevention in kidney transplantationSylvie Euvrard, Emmanuel Morelon, Lionel Rostaing, et al.
Journal of the American Academy of Dermatology|June 21, 2021
Late-onset adverse events of anti-PD1 therapy in melanoma patients: An observational study from MELBASE, a nationwide prospective cohortClémentine Carlet, Stéphane Dalle, Marie-Thérèse Leccia, et al.
Frontiers in Oncology|November 8, 2023
Differential gradients of immunotherapy vs targeted therapy efficacy according to the sun-exposure pattern of the site of occurrence of primary melanoma: a multicenter prospective cohort study (MelBase)David Russo, Stéphane Dalle, Olivier Dereure, et al.
JAMA Oncology|October 8, 2020
Effect of Weekly Paclitaxel With or Without Bevacizumab on Progression-Free Rate Among Patients With Relapsed Ovarian Sex Cord-Stromal Tumors: The ALIENOR/ENGOT-ov7 Randomized Clinical TrialIsabelle Ray-Coquard, Philipp Harter, Domenica Lorusso, et al.
Nature Cell Biology|February 12, 2024
Biomolecular condensation orchestrates clathrin-mediated endocytosis in plantsJonathan Michael Dragwidge, Yanning Wang, Lysiane Brocard, et al.
Multiple Sclerosis and Related Disorders|July 15, 2023
The biological sample collection of the OFSEP French MS registry: An essential tool dedicated to researchersGuillaume Brocard, Romain Casey, Nathalie Dufay, et al.
Journal of the American Academy of Dermatology|December 21, 2022
Impact of systemic therapies in metastatic melanoma of unknown primary: A study from MELBASE, a French multicentric prospective cohortPerrine Rousset, Stéphane Dalle, Laurent Mortier, et al.
Pageof 46

Showing results (411-420 of 455) with videos related to

Sort By:
Pageof 46
Melanoma Research|November 11, 2024
Real-life effectiveness on overall survival of continued immune checkpoint inhibition following progression in advanced melanoma: estimation from the Melbase cohortCamille Macaire, Wendy Lefevre, Sophie Dalac, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 18, 2018
Sirolimus for Secondary Prevention of Skin Cancer in Kidney Transplant Recipients: 5-Year ResultsJacques Dantal, Emmanuel Morelon, Lionel Rostaing, et al.
Archives of Dermatology|March 17, 2010
The role of circumstances of diagnosis and access to dermatological care in early diagnosis of cutaneous melanoma: a population-based study in FranceFrédérique Durbec, Fabien Vitry, Florence Granel-Brocard, et al.
The New England Journal of Medicine|July 27, 2012
Sirolimus and secondary skin-cancer prevention in kidney transplantationSylvie Euvrard, Emmanuel Morelon, Lionel Rostaing, et al.
Journal of the American Academy of Dermatology|June 21, 2021
Late-onset adverse events of anti-PD1 therapy in melanoma patients: An observational study from MELBASE, a nationwide prospective cohortClémentine Carlet, Stéphane Dalle, Marie-Thérèse Leccia, et al.
Frontiers in Oncology|November 8, 2023
Differential gradients of immunotherapy vs targeted therapy efficacy according to the sun-exposure pattern of the site of occurrence of primary melanoma: a multicenter prospective cohort study (MelBase)David Russo, Stéphane Dalle, Olivier Dereure, et al.
JAMA Oncology|October 8, 2020
Effect of Weekly Paclitaxel With or Without Bevacizumab on Progression-Free Rate Among Patients With Relapsed Ovarian Sex Cord-Stromal Tumors: The ALIENOR/ENGOT-ov7 Randomized Clinical TrialIsabelle Ray-Coquard, Philipp Harter, Domenica Lorusso, et al.
Nature Cell Biology|February 12, 2024
Biomolecular condensation orchestrates clathrin-mediated endocytosis in plantsJonathan Michael Dragwidge, Yanning Wang, Lysiane Brocard, et al.
Multiple Sclerosis and Related Disorders|July 15, 2023
The biological sample collection of the OFSEP French MS registry: An essential tool dedicated to researchersGuillaume Brocard, Romain Casey, Nathalie Dufay, et al.
Journal of the American Academy of Dermatology|December 21, 2022
Impact of systemic therapies in metastatic melanoma of unknown primary: A study from MELBASE, a French multicentric prospective cohortPerrine Rousset, Stéphane Dalle, Laurent Mortier, et al.
Pageof 46